Navigation Links
MS Drug Fails The Test For Treating Crohns Disease

Biogen Idec's chief executive, James Mullen is not a happy man. The Cambridge biotechnology company is not likely to receive approval from European regulators to use its drug Tysabri to treat patients with Crohn's disease, a debilitating intestinal ailment.

Results from drug trials that were included in an application to the European Medicines Agency were marked as "interesting but need more development". Now, an additional clinical trial proposed by the agency could take years and cost Biogen Idec millions of dollars, says Mullen.

Biogen Idec and Elan Corp. of Ireland have partnered on development of Tysabri since 2001. After showing promising results in testing, the drug was introduced in the United States in November 2004 to treat patients with multiple sclerosis, but was abruptly withdrawn from the market after the companies found two patients in Tysabri trials had contracted a potentially fatal brain disease. Ultimately, three patients were found to have contracted the brain disease, progressive multifocal leukoencephalopathy, or PML, and two died from it.

Yet, after impassioned testimonies from multiple sclerosis patients anxious for a chance to try Tysabri, the Food and Drug Administration permitted sales to resume, but Biogen Idec was required to take additional safety precautions, including a mandatory registry of patients receiving the drug.

In recent public statements, officials from Biogen Idec and Elan touted Tysabri's ability to induce remission in Crohn's patients. In their partnership, Biogen Idec has led trials and regulatory filings related to multiple sclerosis, and Elan has overseen the potential expansion of Tysabri as a treatment for Crohn's disease. "The data suggest that Tysabri could be an alternative biologic choice for Crohn's disease patients, says Elan.As the data continue to unfold, [Elan and Biogen Idec] will explore additional indications, as appropriate, to unmet medical needs", the company was quoted.

In a comprehensive safety review last year, the companies found two multiple sclerosis patients with PML who were also being treated with Biogen Idec's drug Avonex, another treatment for multiple sclerosis. One of those patients survived. Another patient in a Crohn's trial, who died from PML, had been treated with immunosuppressants.

This pattern, according to experts, suggests that the risks of contracting PML while using Tysabri could increase if a patient is also being given a drug that affects the immune system. If so, that raises the risks of treating Crohn's patients with Tysabri, because many have weakened immune systems.

"Against the backdrop of PML, where you have a set of patients that already get bombarded with immunosuppressants over 20 to 30 years, [Crohn's] is not the first place we'd go to develop Tysabri," states Mullen. According to him, the drug looks more promising as a treatment for Lupus and certain cancers.


'"/>




Related medicine news :

1. Alcoholism Drug Fails To Prevent Drinking Relapses
2. Tamiflu Fails To Save Two Lives
3. Himachal Pradesh Fails To Become Health Tourism Center
4. Budhias Medical Report Fails to Address Long Term Health Issues
5. "Daydreaming" Network Fails In Autism
6. 72-year-old Bachelor of Rajasthan Fails Class 10 Again!
7. Already Short Staffed And In Deficit NHS Fails To Supply Staff For IT Project
8. NHS 24 Fails To Save a Retired Nurse
9. Smartcard Legislation Fails The Privacy Test - AMA
10. Support Fails Rural Heart Patients
11. Steroid Use Fails to Boost Pregnancy Rates in Infertility Treatments
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical ... Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. ... honor of Morris F. Collen, a pioneer in the field of medical informatics, this ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa ... contributed a medical article to the newly revamped Cosmetic Town journal ... the hair transplant procedure known as Follicular Unit Extraction (FUE). , ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health ... Miles by Moonlight to raise money for the American Heart Association Heart Walk. Teams ... Teams will work together to keep their treadmills moving for 5 hours. Treadmills will ...
(Date:10/12/2017)... ... October 12, 2017 , ... In ... taxes a year. In some states—like New York, New Jersey, Massachusetts, Texas, Virginia, ... overseas retirement havens have extremely low property-tax rates, which contributes to the relatively ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... COPENHAGEN, Denmark , Oct. 2, 2017 The ... tool in the struggle to reverse the tide of prescription ... plan for regulating their medicine intake and stepping down their ... is set to launch in December 2017; the first 100,000 ... access. Learn more at http://www.rebound-solution.com/ ...
(Date:9/27/2017)...  Commended for their devotion to personalized service, SMP Pharmacy ... one in the South Florida Business Journal,s 50 Fastest-Growing Companies, ... list, the national specialty pharmacy has found its niche.  To ... soon be honored by SFBJ as the 2017 Power Leader ... to receive his award in October, Bardisa said of the ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
Breaking Medicine Technology: